scholarly journals Size Matters: Metastatic cluster size and stromal recruitment in the establishment of successful prostate cancer to bone metastases

2017 ◽  
Author(s):  
Arturo Araujo ◽  
Leah M. Cook ◽  
Conor C. Lynch ◽  
David Basanta

AbstractProstate cancer (PCa) impacts over 180,000 men every year in the US alone with 26,000 patients expected to succumb to the disease (cancer.gov). The primary cause of death is metastasis, with secondary lesions most commonly occurring in the skeleton. Prostate cancer to bone metastasis is an important yet poorly understood process that is difficult to explore with experimental techniques alone. To this end we have utilized a hybrid (discrete-continuum) cellular automata (HCA) model of normal bone matrix homeostasis that allowed us to investigate how metastatic PCa can disrupt the bone microenvironment. Our previously published results showed that PCa cells can recruit mesenchymal stem cells (MSCs) that give rise to bone building osteoblasts. MSCs are also thought to be complicit in the establishment of successful bone metastases (1). Here we have explored aspects of early metastatic colonization and shown that the size of PCa clusters needs to be within a specific range to become successfully established: sufficiently large to maximize success but not too large to risk failure through competition amongst cancer and stromal cells for scarce resources. Furthermore, we show that MSC recruitment can promote the establishment of a metastasis and compensate for relatively low numbers of PCa cells seeding the bone microenvironment. Combined, our results highlight the utility of computational models that capture the complex and dynamic dialogue between cells during the initiation of active metastases.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 5003-5003
Author(s):  
Evan Y. Yu ◽  
Fenghai Duan ◽  
Mark Muzi ◽  
Jeremy Gorelick ◽  
Bennett Chin ◽  
...  

5003 Background: Dasatinib is a SRC kinase inhibitor that decreases bone turnover in men with metastatic castration-resistant prostate cancer (mCRPC). 18F-fluoride PET was used to evaluate differential response between normal and tumor bone to dasatinib. Methods: Patients with bone mCRPC underwent dynamic 18F-flouride PET imaging prior to and 12 weeks after dasatinib treatment. Up to 5 bone metastases with matching normal bone regions were selected for analysis by SUVmax, Ki, K1and Patlak flux. Their pre-treatment values and change from pre-treatment to post-treatment values were evaluated via generalized estimating equations to predict skeletal-related events (SRE) and via Cox proportional hazards modeling to predict progression-free survival (PFS) with Prostate Cancer Working Group 2 criteria, overall survival and time to SRE. Results: Eighteen patients treated with dasatinib underwent baseline 18F-flouride PET imaging; 12 had follow-up scans allowing assessment of changes due to therapy. Median age for all patients was 69 (range 48-86) years. Significant decrease in SUVmax (p=0.0002) occurred in bone metastases with dasatinib while significant increases in Patlak flux (p=0.0033) occurred in normal bone. Significant differences in changes from tumor bone compared to normal bone in response to dasatinib were noted for SUVmax (p<0.0001). Of 18 patients, 17 have either met progression criteria or death by the time of this analysis. Decrease in tumor bone SUVmax (p=0.019), Ki(p=0.022), and Patlak flux (p=0.034) from pre-treatment to post-treatment correlates with longer PFS. Conclusions: 18F-fluoride PET indicates differential effect of dasatinib on tumor compared to normal bone in men with mCRPC. In patients undergoing pre- and post-dasatinib 18F-fluoride PET imaging a decrease in bone mCRPC fluoride uptake in response to treatment correlates with PFS. Clinical trial information: NCT00936975.


2015 ◽  
Vol 75 (11) ◽  
pp. 2151-2158 ◽  
Author(s):  
Joseph L. Sottnik ◽  
Jinlu Dai ◽  
Honglai Zhang ◽  
Brittany Campbell ◽  
Evan T. Keller

2016 ◽  
Vol 10s1 ◽  
pp. CMO.Ss30751 ◽  
Author(s):  
Joelle El-Amm ◽  
Jeanny B. Aragon-Ching

Skeletal involvement in metastatic castrate-resistant prostate cancer (mCRPC) is common and results in significant morbidity and mortality. The interaction of prostate cancer with the bone microenvironment contributes to progression of cancer in the bone leading to skeletal-related events (SREs). Studies aimed at targeting the bone have been carried out over the recent years. Bisphosphonates are synthetic pyrophosphate analogs first investigated for their role in SRE prevention with zoledronic acid as the main bisphosphonate that is approved by the US Food and Drug Administration for retardation of skeletal events in men with metastatic prostate cancer. Denosumab is another bone-targeted agent against uncontrolled osteolysis and serves as a RANK ligand inhibitor, superior to zoledronic acid in delaying SREs. Radiopharmaceuticals have played a role in targeting the bone microenvironment mainly in pain palliation in mCRPC utilizing strontium or samarium in the remote past, but only radium-223 is the first radiopharmaceutical that has yielded improvement in overall survival. The combination and sequencing strategies of these agents is the subject of multiple ongoing trials to guide the best use of these emerging agents.


2019 ◽  
Vol 60 (12) ◽  
pp. 1713-1716 ◽  
Author(s):  
Helle D. Zacho ◽  
Mads R. Jochumsen ◽  
Niels C. Langkilde ◽  
Jesper C. Mortensen ◽  
Christian Haarmark ◽  
...  

2007 ◽  
Vol 35 (4) ◽  
pp. 701-703 ◽  
Author(s):  
I. Podgorski ◽  
B.E. Linebaugh ◽  
B.F. Sloane

The skeleton is the most common site of metastasis in patients with advanced prostate cancer. Despite many advances in targeting skeletal metastases, the mechanisms behind the attraction of prostate cancer cells to the bone are not known. Osteoclast cathepsin K, due to its ability to effectively degrade bone matrix collagen I, has been implicated in colonization and growth of prostate tumours in the bone. Identification of new cathepsin K substrates in the bone microenvironment and the recent findings demonstrating its involvement in obesity and inflammation suggest additional roles for this enzyme in skeletal metastases of prostate cancer.


2012 ◽  
Vol 30 (4) ◽  
pp. 541-552 ◽  
Author(s):  
Afshin Varzavand ◽  
Justin M. Drake ◽  
Robert U. Svensson ◽  
Mary E. Herndon ◽  
Bo Zhou ◽  
...  

2016 ◽  
Author(s):  
Arturo Araujo ◽  
David Basanta

AbstractProstate to bone metastases induce a “vicious cycle” by promoting excessive osteoclast and osteoblast mediated bone degradation and formation that in turn yields factors that drive cancer growth. Recent advances defining the molecular mechanisms that control the vicious cycle have revealed new therapeutic targeting opportunities. However, given the complex temporal and simultaneous cellular interactions occurring in the bone microenvironment, assessing the impact of putative therapies is challenging. To this end, we have integrated biological and computational approaches to generate an accurate model of normal bone matrix homeostasis and the prostate cancer-bone microenvironment. The model faithfully reproduces the basic multicellular unit (BMU) bone coupling process and introduction of a single prostate cancer cell yields a vicious cycle that is similar in cellular composition and pathophysiology to models of prostate to bone metastasis.


Sign in / Sign up

Export Citation Format

Share Document